By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001

Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.

Key Statistics

Ownership: Public

Web Site: Seattle Genetics, Inc.
Symbol: SGEN



Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 


Company News
Atara Biotherapeutics (ATRA) Appoints Eric Dobmeier, Chief Operating Officer Of Seattle Genetics, Inc. (SGEN) To Its Board Of Directors 3/27/2015 6:16:34 AM
Seattle Genetics, Inc. (SGEN) To Present At Upcoming Investor Conferences 2/25/2015 10:55:00 AM
Seattle Genetics, Inc. (SGEN) Submits Supplemental BLA To FDA For Phase 3 AETHERA Trial Of ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At High Risk Of Relapse 2/18/2015 8:48:42 AM
Seattle Genetics, Inc. (SGEN) Reports Fourth Quarter and Year 2014 Financial Results 2/11/2015 11:52:19 AM
Seattle Genetics, Inc. (SGEN) To Present At Leerink Global Healthcare Conference 2/5/2015 11:53:48 AM
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2014 Financial Results On February 10, 2015 1/21/2015 11:27:31 AM
Seattle Genetics, Inc. (SGEN) And Bristol-Myers Squibb Company (BMY) Announce Clinical Collaboration To Evaluate Combination Of Adcetris® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Hematologic Malignancies 1/12/2015 11:20:12 AM
Seattle Genetics, Inc. (SGEN) To Present At The J.P. Morgan Healthcare Conference 1/6/2015 11:50:37 AM
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014 10:45:08 AM
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY) ADCETRIS Phase 3 Demonstrated Statistically Significant Improvement In Progression-Free Survival 12/9/2014 8:06:20 AM